Trial Outcomes & Findings for Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis (NCT NCT00141921)

NCT ID: NCT00141921

Last Updated: 2017-10-05

Results Overview

A serious adverse events is any AE that * is fatal * is life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other significant medical hazard. The severity assessment for adverse events and infections (except injection site reactions) was done using the Common Toxicity Criteria (CTC) Version 2.0, where Grade 3 indicates a severe toxicity (incapacitating with inability to work or do usual activity). An infectious event is an event that was considered by the investigator to be an infectious episode. An injection site reaction is a reaction at the site of the subcutaneous injection, commonly characterized, but not limited to symptoms of erythema (redness, usually raised), pruritis (itching), swelling, or pain that is persistent for 4 hours or longer.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

182 participants

Primary outcome timeframe

264 Weeks

Results posted on

2017-10-05

Participant Flow

This study was designed to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe plaque psoriasis who participated in Study 20030211 (NCT00078819). The study was conducted at 38 sites in the United States and Canada.

Results reported below are from the main analysis performed at year 5 (264 weeks).

Participant milestones

Participant milestones
Measure
Etanercept
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Overall Study
STARTED
182
Overall Study
Received Treatment
181
Overall Study
COMPLETED
41
Overall Study
NOT COMPLETED
141

Reasons for withdrawal

Reasons for withdrawal
Measure
Etanercept
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Overall Study
Remain on Study
28
Overall Study
Withdrawal by Subject
42
Overall Study
Lost to Follow-up
19
Overall Study
Noncompliance
17
Overall Study
Disease Progression
7
Overall Study
Protocol Deviation
7
Overall Study
Adverse Event
5
Overall Study
Administrative Decision
2
Overall Study
Pregnancy
4
Overall Study
Ineligibility Determined
2
Overall Study
Other
8

Baseline Characteristics

Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Etanercept
n=182 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Age, Continuous
12.8 years
STANDARD_DEVIATION 3.5 • n=5 Participants
Sex: Female, Male
Female
90 Participants
n=5 Participants
Sex: Female, Male
Male
92 Participants
n=5 Participants
Race/Ethnicity, Customized
White or Caucasian
138 participants
n=5 Participants
Race/Ethnicity, Customized
Black or African American
10 participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic or Latino
17 participants
n=5 Participants
Race/Ethnicity, Customized
Asian
13 participants
n=5 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
1 participants
n=5 Participants
Race/Ethnicity, Customized
Other
3 participants
n=5 Participants

PRIMARY outcome

Timeframe: 264 Weeks

Population: Participants who received at least one dose of investigational product.

A serious adverse events is any AE that * is fatal * is life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other significant medical hazard. The severity assessment for adverse events and infections (except injection site reactions) was done using the Common Toxicity Criteria (CTC) Version 2.0, where Grade 3 indicates a severe toxicity (incapacitating with inability to work or do usual activity). An infectious event is an event that was considered by the investigator to be an infectious episode. An injection site reaction is a reaction at the site of the subcutaneous injection, commonly characterized, but not limited to symptoms of erythema (redness, usually raised), pruritis (itching), swelling, or pain that is persistent for 4 hours or longer.

Outcome measures

Outcome measures
Measure
Etanercept
n=181 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Number of Participants With Adverse Events
Any adverse event
161 participants
Number of Participants With Adverse Events
Non-infectious adverse events
149 participants
Number of Participants With Adverse Events
Infections
140 participants
Number of Participants With Adverse Events
Grade 3 non-infectious adverse events
14 participants
Number of Participants With Adverse Events
Grade 3 infections
5 participants
Number of Participants With Adverse Events
Serious non-infectious adverse events
5 participants
Number of Participants With Adverse Events
Serious infections
2 participants
Number of Participants With Adverse Events
Non-infectious AEs leading to study withdrawal
5 participants
Number of Participants With Adverse Events
Infections leading to withdrawal from study
1 participants
Number of Participants With Adverse Events
Injection site reactions
16 participants
Number of Participants With Adverse Events
Deaths
0 participants

SECONDARY outcome

Timeframe: 264 weeks

Population: Participants who received at least one dose of investigational product.

An injection site reaction is a reaction at the site of the subcutaneous injection, commonly characterized, but not limited to symptoms of erythema (redness, usually raised), pruritis (itching), swelling, or pain that is persistent for 4 hours or longer.

Outcome measures

Outcome measures
Measure
Etanercept
n=181 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Number of Participants With Injection Site Reactions
Any injection site reaction
16 participants
Number of Participants With Injection Site Reactions
Injection site erythema
6 participants
Number of Participants With Injection Site Reactions
Injection site reaction
4 participants
Number of Participants With Injection Site Reactions
Injection site pruritus
3 participants
Number of Participants With Injection Site Reactions
Injection site haematoma
2 participants
Number of Participants With Injection Site Reactions
Injection site swelling
2 participants
Number of Participants With Injection Site Reactions
Injection site discolouration
1 participants
Number of Participants With Injection Site Reactions
Injection site irritation
1 participants
Number of Participants With Injection Site Reactions
Injection site pain
1 participants

SECONDARY outcome

Timeframe: 264 weeks

Population: Participants who received at least one dose of investigational product.

The exposure adjusted event rate for a given event in a given time period is defined as the number of events reported in the given time period divided by total patient-years on investigational product during the period. Exposure-adjusted event rate per 100 patient years = total number of events / patient years \* 100. Multiple occurrences of the same event for a participant were counted as multiple events.

Outcome measures

Outcome measures
Measure
Etanercept
n=181 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Exposure-adjusted Adverse Event Rates
All adverse events
215.8 events per 100 patient years
Exposure-adjusted Adverse Event Rates
Non-infectious Adverse Events
115.9 events per 100 patient years
Exposure-adjusted Adverse Event Rates
Infections
97.3 events per 100 patient years
Exposure-adjusted Adverse Event Rates
Injection Site Reactions
2.6 events per 100 patient years

SECONDARY outcome

Timeframe: 264 weeks

Population: Participants who received at least one dose of investigational product.

Outcome measures

Outcome measures
Measure
Etanercept
n=181 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Number of Participants With Clinically Significant Changes in Vital Signs
0 participants

SECONDARY outcome

Timeframe: 264 weeks

Population: Participants who received at least one dose of investigational product.

The severity assessment for adverse events and infections (not including injection site reaction) used the Common Toxicity Criteria (CTC) Version 2.0, where Grade 1= Mild - aware of sign or symptom, but easily tolerated; Grade 2= Moderate - discomfort enough to cause interference with usual activity; Grade 3 = Severe - incapacitating with inability to work or do usual activity; Grade 4= Life-threatening - refers to an event in which the patient was, in the view of the investigator, at risk of immediate death at the time of event; Grade 5 = Fatal.

Outcome measures

Outcome measures
Measure
Etanercept
n=181 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Number of Participants With Grade 3 and 4 Laboratory Toxicities
Grade 3 high creatinine
1 participants
Number of Participants With Grade 3 and 4 Laboratory Toxicities
Grade 3 high hemoglobin
1 participants
Number of Participants With Grade 3 and 4 Laboratory Toxicities
Grade 3 low hemoglobin
1 participants
Number of Participants With Grade 3 and 4 Laboratory Toxicities
Grade 3 high alanine aminotransferase
1 participants
Number of Participants With Grade 3 and 4 Laboratory Toxicities
Grade 3 high white blood cells
1 participants
Number of Participants With Grade 3 and 4 Laboratory Toxicities
Any grade 4 toxicity
0 participants

SECONDARY outcome

Timeframe: 264 weeks

Population: Participants who received at least one dose of investigational product and had a post-baseline antibody result.

Binding antibodies to etanercept were detected using an anti-etanercept immunoassay. The positive samples in the immunoassay were further analyzed for the presence of neutralizing antibodies using a bioassay. Participants who developed anti-etanercept antibodies are those who were antibody positive post-baseline with a negative or no result at baseline.

Outcome measures

Outcome measures
Measure
Etanercept
n=169 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Number of Participants Who Developed Anti-etanercept Antibodies
Binding antibody positive
18 participants
Number of Participants Who Developed Anti-etanercept Antibodies
Neutralizing antibody positive
0 participants

SECONDARY outcome

Timeframe: Baseline and weeks 12, 48, 96, 144, 192, 240 and 264

Population: Participants who received at least one dose of investigational product and with available data at each time point.

A PASI 50 response is a 50% or greater improvement (reduction) from baseline in PASI score. The PASI measures the average redness (erythema), thickness (induration), and scaliness (each graded on a 0 to 4 scale) of psoriasis lesions, weighted by the area of involvement in the four main body areas (i.e., head and neck, trunk, upper extremities, and lower extremities). PASI scores can range from 0.0 to 72.0, with higher scores indicating greater severity and/or more extensive psoriasis.

Outcome measures

Outcome measures
Measure
Etanercept
n=181 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percentage of Participants With a Psoriasis Area and Severity Index 50 Response (PASI 50)
Week 12 (N = 181)
89.5 percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 Response (PASI 50)
Week 48 (N = 168)
89.3 percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 Response (PASI 50)
Week 96 (N = 138)
89.1 percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 Response (PASI 50)
Week 144 (N = 114)
88.6 percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 Response (PASI 50)
Week 192 (n = 92)
87.0 percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 Response (PASI 50)
Week 240 (N = 74)
91.9 percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 Response (PASI 50)
Week 264 (N = 66)
87.9 percentage of participants

SECONDARY outcome

Timeframe: Baseline and weeks 12, 48, 96, 144, 192, 240 and 264

Population: Participants who received at least one dose of investigational product with available data at each time point.

A PASI 75 response is a 75% or greater improvement (reduction) from baseline in PASI score. The PASI measures the average redness (erythema), thickness (induration), and scaliness (each graded on a 0 to 4 scale) of psoriasis lesions, weighted by the area of involvement in the four main body areas (i.e., head and neck, trunk, upper extremities, and lower extremities). PASI scores can range from 0.0 to 72.0, with higher scores indicating greater severity and/or more extensive psoriasis.

Outcome measures

Outcome measures
Measure
Etanercept
n=181 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percentage of Participants With a PASI 75 Response
Week 12 (N = 181)
67.4 percentage of participants
Percentage of Participants With a PASI 75 Response
Week 48 (N = 168)
67.3 percentage of participants
Percentage of Participants With a PASI 75 Response
Week 96 (N = 138)
60.9 percentage of participants
Percentage of Participants With a PASI 75 Response
Week 144 (N = 114)
62.3 percentage of participants
Percentage of Participants With a PASI 75 Response
Week 192 (n = 92)
69.6 percentage of participants
Percentage of Participants With a PASI 75 Response
Week 240 (N = 74)
64.9 percentage of participants
Percentage of Participants With a PASI 75 Response
Week 264 (N = 66)
63.6 percentage of participants

SECONDARY outcome

Timeframe: Baseline and weeks 12, 48, 96, 144, 192, 240 and 264

Population: Participants who received at least one dose of investigational product with available data at each time point.

A PASI 90 response is a 90% or greater improvement (reduction) from baseline in PASI score. The PASI measures the average redness (erythema), thickness (induration), and scaliness (each graded on a 0 to 4 scale) of psoriasis lesions, weighted by the area of involvement in the four main body areas (i.e., head and neck, trunk, upper extremities, and lower extremities). PASI scores can range from 0.0 to 72.0, with higher scores indicating greater severity and/or more extensive psoriasis.

Outcome measures

Outcome measures
Measure
Etanercept
n=181 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percentage of Participants With a PASI 90 Response
Week 12 (N = 181)
35.4 percentage of participants
Percentage of Participants With a PASI 90 Response
Week 48 (N = 168)
32.7 percentage of participants
Percentage of Participants With a PASI 90 Response
Week 96 (N = 138)
29.7 percentage of participants
Percentage of Participants With a PASI 90 Response
Week 144 (N = 114)
28.1 percentage of participants
Percentage of Participants With a PASI 90 Response
Week 192 (n = 92)
35.9 percentage of participants
Percentage of Participants With a PASI 90 Response
Week 240 (N = 74)
36.5 percentage of participants
Percentage of Participants With a PASI 90 Response
Week 264 (N = 66)
28.8 percentage of participants

SECONDARY outcome

Timeframe: Study 20030211 baseline, Study 20050111 baseline and weeks 12, 48, 96, 144, 192, 240 and 264

Population: Participants who received at least one dose of investigational product with available data at each time point.

The PASI measures the average redness (erythema), thickness (induration), and scaliness (each graded on a 0 to 4 scale) of psoriasis lesions, weighted by the area of involvement in the four main body areas (i.e., head and neck, trunk, upper extremities, and lower extremities). PASI scores can range from 0.0 to 72.0, with higher scores indicating greater severity and/or more extensive psoriasis. Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline Value \* 100.

Outcome measures

Outcome measures
Measure
Etanercept
n=181 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percent Improvement From Study 20030211 Baseline in PASI Score
Study 20050111 baseline (N = 179)
74.429 percent improvement
Standard Deviation 22.146
Percent Improvement From Study 20030211 Baseline in PASI Score
Week 12 (N = 181)
78.286 percent improvement
Standard Deviation 21.079
Percent Improvement From Study 20030211 Baseline in PASI Score
Week 48 (N = 168)
77.546 percent improvement
Standard Deviation 20.682
Percent Improvement From Study 20030211 Baseline in PASI Score
Week 96 (N = 138)
75.355 percent improvement
Standard Deviation 24.139
Percent Improvement From Study 20030211 Baseline in PASI Score
Week 144 (N = 114)
75.052 percent improvement
Standard Deviation 23.839
Percent Improvement From Study 20030211 Baseline in PASI Score
Week 192 (n = 92)
77.815 percent improvement
Standard Deviation 23.965
Percent Improvement From Study 20030211 Baseline in PASI Score
Week 240 (N = 74)
78.924 percent improvement
Standard Deviation 23.497
Percent Improvement From Study 20030211 Baseline in PASI Score
Week 264 (N = 66)
74.605 percent improvement
Standard Deviation 29.327

SECONDARY outcome

Timeframe: Weeks 12, 48, 96, 144, 192, 240 and 264

Population: Participants who received at least one dose of investigational product with available data at each time point.

The sPGA is a 6-point scale ranging from 0 (clear) to 5 (very severe) used to measure the severity of disease (induration, scaling, and erythema). A sPGA response is defined as a sPGA value of clear (score 0) or almost clear (score 1).

Outcome measures

Outcome measures
Measure
Etanercept
n=181 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1)
Week 264 (N = 66)
37.9 percentage of participants
Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1)
Week 12 (N = 181)
53.6 percentage of participants
Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1)
Week 48 (N = 168)
48.8 percentage of participants
Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1)
Week 96 (N = 139)
47.5 percentage of participants
Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1)
Week 144 (N = 114)
45.6 percentage of participants
Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1)
Week 192 (n = 92)
47.8 percentage of participants
Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1)
Week 240 (N = 74)
50.0 percentage of participants

SECONDARY outcome

Timeframe: Study 20030211 baseline, Study 20050111 baseline and weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 and 264

Population: Participants who received at least one dose of investigational product with baseline data, and with available data at each time point.

The Children's Dermatology Life Quality Index (CDLQI) was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (Not at all) to 3 (Very much). The total score ranges from 0 to 30, with lower scores indicating better quality of life. If participants were ≥ 13 years old, the text instrument was completed by the participants themselves. Participants ≥ 8 but \< 13 years old used the cartoon version of the instrument and participants ≤ 7 years old used the cartoon version of the instrument completed with help from the parents or caregivers. Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline Value \* 100.

Outcome measures

Outcome measures
Measure
Etanercept
n=173 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Study 20050111 baseline (N = 164)
59.492 percent improvement
Standard Deviation 73.501
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 24 (N = 155)
54.978 percent improvement
Standard Deviation 69.744
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 48 (N = 148)
59.229 percent improvement
Standard Deviation 65.259
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 72 (N = 136)
57.549 percent improvement
Standard Deviation 79.389
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 96 (N = 127)
61.084 percent improvement
Standard Deviation 66.169
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 120 (N = 105)
64.059 percent improvement
Standard Deviation 75.298
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 144 (N = 103)
69.732 percent improvement
Standard Deviation 42.008
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 168 (N = 93)
67.531 percent improvement
Standard Deviation 42.261
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 192 (N = 81)
65.622 percent improvement
Standard Deviation 53.359
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 216 (N = 70)
76.121 percent improvement
Standard Deviation 43.217
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 240 (N = 64)
73.631 percent improvement
Standard Deviation 54.704
Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
Week 264 (N = 56)
63.291 percent improvement
Standard Deviation 63.555

SECONDARY outcome

Timeframe: Study 20030211 baseline, Study 20050111 baseline and weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 and 264

Population: Participants who received at least one dose of investigational product with baseline data and with available data at each time point.

The Children's Dermatology Life Quality Index (CDLQI) was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (not at all) to 3 (Very much). The CDLQI Symptoms and Feelings Score includes 2 questions and ranges from 0 to 6, with lower scores indicating better quality of life. Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline Value \* 100.

Outcome measures

Outcome measures
Measure
Etanercept
n=173 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Study 20050111 baseline (N = 165)
54.869 percent improvement
Standard Deviation 56.213
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 24 (N = 155)
55.366 percent improvement
Standard Deviation 64.039
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 48 (N = 149)
53.792 percent improvement
Standard Deviation 65.857
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 72 (N = 136)
51.005 percent improvement
Standard Deviation 68.117
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 96 (N = 128)
55.430 percent improvement
Standard Deviation 57.430
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 120 (N = 105)
53.302 percent improvement
Standard Deviation 67.555
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 144 (N = 104)
56.250 percent improvement
Standard Deviation 58.194
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 168 (N = 94)
58.901 percent improvement
Standard Deviation 49.431
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 192 (N = 81)
55.700 percent improvement
Standard Deviation 56.352
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 216 (N = 71)
71.056 percent improvement
Standard Deviation 41.396
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 240 (N = 65)
67.538 percent improvement
Standard Deviation 43.418
Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score
Week 264 (N = 57)
56.725 percent improvement
Standard Deviation 52.965

SECONDARY outcome

Timeframe: Study 20030211 baseline, Study 20050111 baseline and weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 and 264

Population: Participants who received at least one dose of investigational product with baseline data and with available data at each time point.

The Children's Dermatology Life Quality Index (CDLQI) was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (not at all) to 3 (Very much). The CDLQI Leisure Score includes 3 questions and ranges from 0 to 9, with lower scores indicating better quality of life. Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline Value \* 100.

Outcome measures

Outcome measures
Measure
Etanercept
n=173 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Study 20050111 baseline (N = 165)
51.088 percent improvement
Standard Deviation 52.612
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 24 (N = 156)
50.546 percent improvement
Standard Deviation 58.606
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 48 (N = 148)
51.792 percent improvement
Standard Deviation 61.204
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 72 (N = 136)
50.792 percent improvement
Standard Deviation 70.769
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 96 (N = 129)
48.686 percent improvement
Standard Deviation 68.482
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 120 (N = 105)
59.031 percent improvement
Standard Deviation 49.472
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 144 (N = 104)
57.125 percent improvement
Standard Deviation 54.284
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 168 (N = 94)
55.198 percent improvement
Standard Deviation 52.141
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 192 (N = 81)
47.989 percent improvement
Standard Deviation 72.947
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 216 (N = 71)
58.545 percent improvement
Standard Deviation 60.440
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 240 (N = 64)
55.727 percent improvement
Standard Deviation 64.420
Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score
Week 264 (N = 56)
50.072 percent improvement
Standard Deviation 62.049

SECONDARY outcome

Timeframe: Study 20030211 baseline, Study 20050111 baseline and weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 and 264

Population: Participants who received at least one dose of investigational product with baseline data and with available data at each time point.

The Children's Dermatology Life Quality Index (CDLQI) was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (not at all) to 3 (Very much). The CDLQI School or Holidays Score includes 1 question (How much did your skin problem effect your school work/holiday plans over the last week?) and ranges from 0 to 3, with lower scores indicating better quality of life. Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline Value \* 100.

Outcome measures

Outcome measures
Measure
Etanercept
n=173 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Study 20050111 baseline (N = 165)
31.616 percent improvement
Standard Deviation 51.981
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 24 (N = 156)
32.585 percent improvement
Standard Deviation 52.750
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 48 (N = 148)
36.149 percent improvement
Standard Deviation 51.778
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 72 (N = 133)
29.825 percent improvement
Standard Deviation 53.025
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 96 (N = 129)
29.457 percent improvement
Standard Deviation 55.805
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 120 (N = 105)
32.063 percent improvement
Standard Deviation 55.166
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 144 (N = 105)
33.333 percent improvement
Standard Deviation 48.371
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 168 (N = 94)
32.979 percent improvement
Standard Deviation 50.563
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 192 (N = 81)
31.070 percent improvement
Standard Deviation 52.886
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 216 (N = 71)
35.211 percent improvement
Standard Deviation 48.103
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 240 (N = 65)
26.923 percent improvement
Standard Deviation 56.649
Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score
Week 264 (N = 57)
27.193 percent improvement
Standard Deviation 51.815

SECONDARY outcome

Timeframe: Study 20030211 baseline, Study 20050111 baseline and weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 and 264

Population: Participants who received at least one dose of investigational product with baseline data and with available data at each time point.

The Children's Dermatology Life Quality Index (CDLQI) was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (not at all) to 3 (Very much). The CDLQI Personal Relationships Score includes 2 questions and ranges from 0 to 6, with lower scores indicating better quality of life. Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline Value \* 100.

Outcome measures

Outcome measures
Measure
Etanercept
n=173 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Study 20050111 baseline (N = 166)
45.452 percent improvement
Standard Deviation 65.038
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 24 (N = 156)
49.797 percent improvement
Standard Deviation 59.328
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 48 (N = 149)
50.895 percent improvement
Standard Deviation 60.179
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 72 (N = 136)
54.669 percent improvement
Standard Deviation 54.519
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 96 (N = 129)
48.346 percent improvement
Standard Deviation 60.414
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 120 (N = 105)
51.206 percent improvement
Standard Deviation 54.435
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 144 (N = 105)
50.365 percent improvement
Standard Deviation 49.636
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 168 (N = 94)
44.557 percent improvement
Standard Deviation 72.287
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 192 (N = 81)
52.284 percent improvement
Standard Deviation 56.125
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 216 (N = 71)
61.737 percent improvement
Standard Deviation 48.255
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 240 (N = 65)
56.282 percent improvement
Standard Deviation 52.042
Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score
Week 264 (N = 57)
56.140 percent improvement
Standard Deviation 52.481

SECONDARY outcome

Timeframe: Study 20030211 baseline, Study 20050111 baseline and weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 and 264

Population: Participants who received at least one dose of investigational product with baseline data and with available data at each time point.

The Children's Dermatology Life Quality Index (CDLQI) was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (not at all) to 3 (Very much). The CDLQI Sleep Score includes 1 question (How much has your sleep been affected by your skin problems over the last week?) and ranges from 0 to 3, with lower scores indicating better quality of life. Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline Value \* 100.

Outcome measures

Outcome measures
Measure
Etanercept
n=171 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 144 (N = 102)
41.013 percent improvement
Standard Deviation 50.229
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 120 (N = 101)
29.538 percent improvement
Standard Deviation 61.503
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Study 20050111 baseline (N = 161)
36.646 percent improvement
Standard Deviation 56.851
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 24 (N = 153)
36.057 percent improvement
Standard Deviation 60.349
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 48 (N = 144)
31.597 percent improvement
Standard Deviation 56.329
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 72 (N = 132)
34.596 percent improvement
Standard Deviation 57.390
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 96 (N = 127)
32.940 percent improvement
Standard Deviation 55.216
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 168 (N = 93)
37.814 percent improvement
Standard Deviation 49.888
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 192 (N = 81)
34.774 percent improvement
Standard Deviation 54.658
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 216 (N = 71)
35.681 percent improvement
Standard Deviation 50.811
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 240 (N = 65)
39.231 percent improvement
Standard Deviation 48.808
Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score
Week 264 (N = 56)
36.012 percent improvement
Standard Deviation 57.890

SECONDARY outcome

Timeframe: Study 20030211 baseline, Study 20050111 baseline and weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 and 264

Population: Participants who received at least one dose of investigational product with baseline data and with available data at each time point.

The Children's Dermatology Life Quality Index (CDLQI) was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (not at all) to 3 (Very much). The CDLQI Treatment Satisfaction Score includes 1 question (How much of a problem has the treatment for your skin been over the last week?) and ranges from 0 to 3, with lower scores indicating better quality of life. Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline Value \* 100.

Outcome measures

Outcome measures
Measure
Etanercept
n=169 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Study 20050111 baseline (N = 161)
23.085 percent improvement
Standard Deviation 64.713
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 24 (N = 152)
13.268 percent improvement
Standard Deviation 74.987
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 48 (N = 144)
18.634 percent improvement
Standard Deviation 67.750
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 72 (N = 134)
23.383 percent improvement
Standard Deviation 73.210
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 96 (N = 128)
17.969 percent improvement
Standard Deviation 72.561
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 120 (N = 105)
17.778 percent improvement
Standard Deviation 65.709
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 144 (N = 104)
21.795 percent improvement
Standard Deviation 62.924
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 168 (N = 93)
20.430 percent improvement
Standard Deviation 73.849
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 192 (N = 81)
26.955 percent improvement
Standard Deviation 68.443
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 216 (N = 71)
31.455 percent improvement
Standard Deviation 59.598
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 240 (N = 65)
30.513 percent improvement
Standard Deviation 57.703
Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score
Week 264 (N = 56)
37.500 percent improvement
Standard Deviation 64.842

SECONDARY outcome

Timeframe: Study 20030211 baseline, Study 20050111 baseline and weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252 and 264

Population: Participants who received at least one dose of investigational product and who completed the joint pain assessment at Study 20030211 baseline, and with available data at each time point.

Participants were asked to indicate how much joint pain they had experienced in the last 7 days on a visual analog scale (VAS) from no pain on the left end of the line (score = 0) to severe pain on the right side of the line (score = 10). Improvement from baseline = (Baseline Value - Post-baseline Value).

Outcome measures

Outcome measures
Measure
Etanercept
n=41 Participants
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Improvement From Study 20030211 Baseline in Joint Pain
Study 20050111 baseline (N = 31)
1.5 units on a scale
Standard Deviation 2.7
Improvement From Study 20030211 Baseline in Joint Pain
Week 12 (N = 29)
2.3 units on a scale
Standard Deviation 2.5
Improvement From Study 20030211 Baseline in Joint Pain
Week 24 (N = 22)
2.4 units on a scale
Standard Deviation 3.2
Improvement From Study 20030211 Baseline in Joint Pain
Week 36 (N = 22)
1.5 units on a scale
Standard Deviation 3.2
Improvement From Study 20030211 Baseline in Joint Pain
Week 48 (N = 24)
1.5 units on a scale
Standard Deviation 3.5
Improvement From Study 20030211 Baseline in Joint Pain
Week 60 (N = 14)
1.3 units on a scale
Standard Deviation 3.2
Improvement From Study 20030211 Baseline in Joint Pain
Week 72 (N = 16)
2.1 units on a scale
Standard Deviation 3.6
Improvement From Study 20030211 Baseline in Joint Pain
Week 84 (N = 14)
2.9 units on a scale
Standard Deviation 3.0
Improvement From Study 20030211 Baseline in Joint Pain
Week 96 (N = 16)
2.0 units on a scale
Standard Deviation 2.7
Improvement From Study 20030211 Baseline in Joint Pain
Week 108 (N = 14)
2.4 units on a scale
Standard Deviation 3.4
Improvement From Study 20030211 Baseline in Joint Pain
Week 120 (N = 12)
2.4 units on a scale
Standard Deviation 2.9
Improvement From Study 20030211 Baseline in Joint Pain
Week 132 (N = 15)
1.9 units on a scale
Standard Deviation 3.7
Improvement From Study 20030211 Baseline in Joint Pain
Week 144 (N = 12)
1.8 units on a scale
Standard Deviation 4.3
Improvement From Study 20030211 Baseline in Joint Pain
Week 156 (N = 12)
2.5 units on a scale
Standard Deviation 3.8
Improvement From Study 20030211 Baseline in Joint Pain
Week 168 (N = 10)
2.2 units on a scale
Standard Deviation 4.0
Improvement From Study 20030211 Baseline in Joint Pain
Week 180 (N = 11)
2.7 units on a scale
Standard Deviation 3.3
Improvement From Study 20030211 Baseline in Joint Pain
Week 192 (N = 11)
2.5 units on a scale
Standard Deviation 4.2
Improvement From Study 20030211 Baseline in Joint Pain
Week 204 (N = 11)
2.8 units on a scale
Standard Deviation 3.6
Improvement From Study 20030211 Baseline in Joint Pain
Week 216 (N = 9)
2.9 units on a scale
Standard Deviation 3.4
Improvement From Study 20030211 Baseline in Joint Pain
Week 228 (N = 10)
2.8 units on a scale
Standard Deviation 3.6
Improvement From Study 20030211 Baseline in Joint Pain
Week 240 (N = 9)
2.7 units on a scale
Standard Deviation 3.4
Improvement From Study 20030211 Baseline in Joint Pain
Week 252 (N = 8)
3.9 units on a scale
Standard Deviation 3.7
Improvement From Study 20030211 Baseline in Joint Pain
Week 264 (N = 8)
3.9 units on a scale
Standard Deviation 3.3

Adverse Events

Etanercept

Serious events: 7 serious events
Other events: 148 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Etanercept
n=181 participants at risk
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Endocrine disorders
Thyroid cyst
0.55%
1/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders
Intestinal obstruction
0.55%
1/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Cellulitis
0.55%
1/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Infectious mononucleosis
0.55%
1/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders
Osteonecrosis
0.55%
1/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders
Anxiety
0.55%
1/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Surgical and medical procedures
Abortion induced
0.55%
1/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.

Other adverse events

Other adverse events
Measure
Etanercept
n=181 participants at risk
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Gastrointestinal disorders
Abdominal pain upper
6.1%
11/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders
Diarrhoea
6.1%
11/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders
Nausea
7.2%
13/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders
Pyrexia
9.4%
17/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Bronchitis
9.9%
18/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Ear infection
6.6%
12/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Gastroenteritis
7.7%
14/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Gastroenteritis viral
7.7%
14/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Influenza
11.6%
21/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Nasopharyngitis
26.0%
47/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Pharyngitis
8.3%
15/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Pharyngitis streptococcal
14.9%
27/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Sinusitis
13.3%
24/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Upper respiratory tract infection
37.6%
68/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Urinary tract infection
6.6%
12/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations
Viral upper respiratory tract infection
6.1%
11/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications
Ligament sprain
6.1%
11/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications
Procedural pain
6.6%
12/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders
Arthralgia
7.7%
14/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin papilloma
13.3%
24/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders
Headache
21.5%
39/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders
Cough
12.2%
22/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders
Nasal congestion
9.4%
17/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
11.0%
20/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders
Acne
18.2%
33/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders
Dermatitis contact
6.1%
11/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders
Psoriasis
7.7%
14/181 • 264 weeks
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Results disclosure agreements

  • Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
  • Publication restrictions are in place

Restriction type: OTHER